Overexpression of NNMT in Glioma Aggravates Tumor Cell Progression: An Emerging Therapeutic Target

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 27

PMID 35884600

Authors

Wei Sun

Yongxiang Zou

Zheng Cai

Jinxiang Huang

Xinjie Hong

Qiang Liang

Weilin Jin

Affiliations

Soon will be listed here.

Abstract

Purpose: Increasing evidence has revealed that nicotinamide -methyltransferase (NNMT) is a key factor influencing the prognosis of tumors. The present study aimed to investigate the role of NNMT in glioma and to elucidate the associated functional mechanisms.

Methods: Clinical samples were analyzed by immunohistochemical staining and Western blotting to evaluate NNMT expression in glioma and normal brain tissues. The correlation between NNMT expression and glioma was analyzed using the Cancer Genome Atlas (TCGA) database. Additionally, NNMT was knocked down in two types of glioma cells, U87 and U251, to evaluate the invasive ability of these cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate NNMT knockdown in the cells. Furthermore, ELISA was used to determine the balance between nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide hydrogen (NAD/NADH ratio), which verified the altered methylation patterns in the cells. The glioma xenograft mouse models were used to verify the regulatory role of NNMT, GAP43, and SIRT1.

Results: Analysis based on our clinical glioma samples and TCGA database revealed that overexpression of NNMT was associated with poor prognosis of patients. Knockdown of NNMT reduced the invasive ability of glioma cells, and downregulation of its downstream protein GAP43 occurred due to altered cellular methylation caused by NNMT overexpression. Gene Set Enrichment Analysis confirmed that NNMT modulated the NAD-related signaling pathway and showed a negative association between NNMT and SIRT1. Moreover, the regulatory roles of NNMT, GAP43, and SIRT1 were confirmed in glioma xenograft mouse models.

Conclusion: Overexpression of NNMT causes abnormal DNA methylation through regulation of the NAD/NADH ratio, which in turn leads to the downregulation of GAP43 and SIRT1, eventually altering the biological behavior of tumor cells.

Citing Articles

Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance.

Srivastava S, Anbiaee R, Houshyari M, Laxmi , Sridhar S, Ashique S Cancer Cell Int. 2025; 25(1):89.

PMID: 40082966 PMC: 11908050. DOI: 10.1186/s12935-025-03721-1.

Robust Cluster Prediction Across Data Types Validates Association of Sex and Therapy Response in GBM.

Gibbs D, Cioffi G, Aguilar B, Waite K, Pan E, Mandel J Cancers (Basel). 2025; 17(3).

PMID: 39941811 PMC: 11815886. DOI: 10.3390/cancers17030445.

Exploring NNMT: from metabolic pathways to therapeutic targets.

Park J, Shin E, Kim T, Yang J, Ki S, Kang K Arch Pharm Res. 2024; 47(12):893-913.

PMID: 39604638 DOI: 10.1007/s12272-024-01519-9.

Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions.

Li J, Sun W, Zhu X, Mei Y, Li W, Li J Metabolites. 2024; 14(6).

PMID: 38921477 PMC: 11205546. DOI: 10.3390/metabo14060343.

Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.

Sun W, Zhu X, Li J, Mei Y, Li W, Li J Front Pharmacol. 2024; 15:1410479.

PMID: 38919254 PMC: 11196770. DOI: 10.3389/fphar.2024.1410479.

References

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway N . Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017; 7:40714. PMC: 5244380. DOI: 10.1038/srep40714. View

Lu X, Long H . Nicotinamide N-methyltransferase as a potential marker for cancer. Neoplasma. 2018; 65(5):656-663. DOI: 10.4149/neo_2018_171024N680. View

Stupp R, Roila F . Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:126-8. DOI: 10.1093/annonc/mdp151. View

Gao Y, Xuan C, Jin M, An Q, Zhuo B, Chen X . Ubiquitin ligase serves an important role in the development of human glioma. Oncol Lett. 2019; 18(5):4659-4666. PMC: 6781729. DOI: 10.3892/ol.2019.10801. View

Zhu M, Zhao W, Zhao H, Zhang J . Diagnostic and prognostic value of microRNA-193b in patients with glioma and its effect on tumor progression. Oncol Lett. 2019; 18(5):4882-4890. PMC: 6781758. DOI: 10.3892/ol.2019.10819. View

Harmankaya I, Akar S, Ugras S, Guler A, Ezveci H, Aydogdu M . Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. J Obstet Gynaecol. 2020; 41(2):248-253. DOI: 10.1080/01443615.2020.1732891. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Ulanovskaya O, Zuhl A, Cravatt B . NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013; 9(5):300-6. PMC: 3631284. DOI: 10.1038/nchembio.1204. View

van Haren M, Gao Y, Buijs N, Campagna R, Sartini D, Emanuelli M . Esterase-Sensitive Prodrugs of a Potent Bisubstrate Inhibitor of Nicotinamide -Methyltransferase (NNMT) Display Cellular Activity. Biomolecules. 2021; 11(9). PMC: 8466754. DOI: 10.3390/biom11091357. View

10.

Neelakantan H, Wang H, Vance V, Hommel J, McHardy S, Watowich S . Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem. 2017; 60(12):5015-5028. DOI: 10.1021/acs.jmedchem.7b00389. View

11.

Bell E, Zhang P, Fisher B, Macdonald D, McElroy J, Lesser G . Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018; 4(10):1405-1409. PMC: 6117103. DOI: 10.1001/jamaoncol.2018.1977. View

12.

Vuong H, Altibi A, Duong U, Ngo H, Pham T, Fung K . BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis. Mol Neurobiol. 2017; 55(5):3718-3724. DOI: 10.1007/s12035-017-0599-y. View

13.

Palanichamy K, Kanji S, Gordon N, Thirumoorthy K, Jacob J, Litzenberg K . NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability. Clin Cancer Res. 2016; 23(9):2325-2334. PMC: 5413402. DOI: 10.1158/1078-0432.CCR-16-1323. View

14.

Togni L, Mascitti M, Sartini D, Campagna R, Pozzi V, Salvolini E . Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review. Biomolecules. 2021; 11(11). PMC: 8615955. DOI: 10.3390/biom11111594. View

15.

Campagna R, Pozzi V, Sartini D, Salvolini E, Brisigotti V, Molinelli E . Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide -Methyltransferase as a Biomarker in Skin Cancers. Cancers (Basel). 2021; 13(19). PMC: 8508019. DOI: 10.3390/cancers13194943. View

16.

Gao Y, van Haren M, Buijs N, Innocenti P, Zhang Y, Sartini D . Potent Inhibition of Nicotinamide -Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics. J Med Chem. 2021; 64(17):12938-12963. PMC: 8436214. DOI: 10.1021/acs.jmedchem.1c01094. View

17.

Shin J, Park C, Yoon G, Hong S, Choi K . NNMT depletion contributes to liver cancer cell survival by enhancing autophagy under nutrient starvation. Oncogenesis. 2018; 7(8):58. PMC: 6085294. DOI: 10.1038/s41389-018-0064-4. View

18.

Jiang Y, Zhou J, Zou D, Hou D, Zhang H, Zhao J . Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia. EBioMedicine. 2019; 48:36-48. PMC: 6838451. DOI: 10.1016/j.ebiom.2019.09.037. View

19.

Suzuki M, Liao W, Wos F, Johnston A, DeGrazia J, Ishii J . Whole-genome bisulfite sequencing with improved accuracy and cost. Genome Res. 2018; 28(9):1364-1371. PMC: 6120621. DOI: 10.1101/gr.232587.117. View

20.

Song M, Li Y, Miao M, Zhang F, Yuan H, Cao F . High stromal nicotinamide N-methyltransferase (NNMT) indicates poor prognosis in colorectal cancer. Cancer Med. 2020; 9(6):2030-2038. PMC: 7064029. DOI: 10.1002/cam4.2890. View